GLP1R and obesity disorder: Semaglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue recently approved by the US Food and Drug Administration, Health Canada and the UK Medicines and Healthcare products Regulatory Agency for chronic weight management, as an adjunct to lifestyle intervention, at a once‐weekly s.c. dose of 2.4 mg in adults with overweight (with ≥ 1 weight‐related condition) or obesity.17, 18, 19